HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.

Abstract
The management of patients with refractory immune thrombocytopenic purpura (ITP) may be difficult. We describe a rapid-onset very long-term remission (9 years) induced by short-term rituximab monotherapy in a 62-year-old man with treatment-refractory chronic ITP. Over a 30-year period from the original diagnosis to last follow-up, the patient needed renewed treatment twelve times within the first two decades and was subsequently brought in continuous complete remission for the last decade by a single course of rituximab. The effect of rituximab in ITP has previously been described. However, in chronic, treatment-refractory ITP occurring in elderly patients, remission rates tend to be low and of short duration.
AuthorsMichael R Clausen, Erik Segel, Margrethe Brandsborg, Francesco d'Amore
JournalEuropean journal of haematology (Eur J Haematol) Vol. 86 Issue 3 Pg. 256-9 (Mar 2011) ISSN: 1600-0609 [Electronic] England
PMID21166717 (Publication Type: Case Reports, Journal Article)
Copyright© 2011 John Wiley & Sons A/S.
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Immunosuppressive Agents
  • Rituximab
Topics
  • Antibodies, Monoclonal, Murine-Derived (administration & dosage, therapeutic use)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Male
  • Middle Aged
  • Platelet Count
  • Purpura, Thrombocytopenic, Idiopathic (blood, immunology, therapy)
  • Remission Induction
  • Rituximab
  • Self Tolerance
  • Splenectomy
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: